What amount sold does Tinos Therapeutics, Inc. report in Form D filings?

The latest linked filings report $2.3M sold across 1 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was Tinos Therapeutics, Inc.'s most recent SEC filing?

Tinos Therapeutics, Inc.'s most recent Form D filing was on 2026-04-17.

How many investors does Tinos Therapeutics, Inc. have?

The most recent Form D filing lists 3 investor(s).

Tinos Therapeutics, Inc.

CIK: 0002088485·Biotechnology·CAMBRIDGE, MA·Corporation·Founded 2023

Reported Sold

$2,250,000

Total Filings

Identified Offerings

Last Filed

Apr 17, 2026

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Biotechnology industry

SEC EDGAR

Offering filing timeline

Apr 17, 2026Form D/A — Amendment

Reported sold: $2,250,000 · Target: $4,000,000

Rule 506(b)·3 investors

Changed: Reported amount sold, Offering target, Reported investors

Sep 26, 2025Form D — New notice

Reported sold: $1,000,000 · Target: $1,500,000

Rule 506(b)·1 investor

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

Amendment Rate

50%

Latest reported sold across 1 identified offering

$2,250,000

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

Nikolaos Tapinos

Related Person

Appears on 1 filing

David Karambizi

Related Person

Appears on 1 filing

Anastasios Polimenakos

Related Person

Appears on 1 filing

Filing History

Date	Type	Offering target	Reported sold	Investors
Apr 17, 2026	Amendment	$4,000,000	$2,250,000	3
Sep 26, 2025	New	$1,500,000	$1,000,000	1

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

Axelyf, Inc.

Biotechnology

Offering target: $2,700,000

Filed Oct 13, 2026